Chinese Herbal Medicine Versus Placebo for the Treatment Of Chronic Obstructive Pulmonary Disease

Abstract

Background:Chinese herbal medicine (CHM) has been shown to be effective in the treatment of stable chronic obstructive pulmonary disease (COPD) by published meta-analyses. However, disease outcomes were inconsistent and heterogeneity was observed attributed to placebo-controlled studies. We present a protocol for a systematic review aiming to evaluate the clinical efficacy and safety of CHM comparing to placebo in the treatment of stable COPD, to provide robust evidence for the use of CHM in COPD.Methods:We will comprehensively search the following 9 databases from inception to March 2019: Web of Science, PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), Chinese National Knowledge Infrastructure (CNKI), WANFANG Database, Chinese Scientific and Technological Periodical Database (VIP) and Chinese Biomedical Database (CBM), and the Cochrane Library database. All clinical randomized controlled trials comparing CHM to placebo for the treatment of stable COPD in English or Chinese will be included. The primary outcome will be quality of life, symptom score and exacerbation frequency, and the secondary outcomes include traditional Chinese medicine syndrome score and effective rate, lung function, 6-minute walk distance, and adverse events. Data extraction and quality assessment will be performed independently by 2 reviewers. Data synthesis and risk of bias will be assessed using the Review Manager software. This protocol will be conducted according to the Preferred Reporting Item for Systematic Review and Meta-analysis Protocols (PRISMA-P) guidance.Results:This systematic review and meta-analysis will provide a high-quality comprehensive evaluation of the efficacy and safety based on current literature evidence of CHM intervention for stable COPD.Conclusion:The conclusion of this study will present the evidence of whether CHM is an effective and safe intervention for stable COPD patients.

Effects of acetylcysteine on micro-inflammation and pulmonary ventilation in chronic obstructive pulmonary disease exacerbation

“…TNF-α is a pro-inflammatory cytokine that induces the production of other inflammatory mediators, which is elevated in AECOPD and linked with the airway inflammation and the oxidative stress[ 22 ]; (3) Change in the level of CRP in the sputum from baseline to the end of treatment, as measured using the immunoturbidimetric method (model: AU5800, Beckman Coulter, Inc., United States). CRP in sputum reflects local inflammation in the airways, which is increased in AECOPD and is associated with bacterial infection and sputum characteristics[ 23 ]; (4) The change in the IL-6 and TNF-α levels in sputum from baseline to the end of treatment, as measured using the ELISA method (R&D Systems, Inc., United States); and (5) The change in lung ventilation function parameters from baseline to the end of treatment, including FEV1, FVC, and peak expiratory flow (PEF), were measured using a spirometer (model: SP-10, Contec Medical Systems Co., Ltd., China), according to the American Thoracic Society/European Respiratory Society guidelines[ 24 ]. The participants were instructed to perform three maneuvers and the best values were recorded.…”

Integrated Chinese and western medicine for acute guillain-barré syndrome treatment

“…As table 1 shown, there were no statistically significant differences in age, gender, and disease period (P>0.05) in two groups, and the basal features were comparable. symptom in the TCM syndrome score system [24][25][26][27]. A score of 4 or more was set for diagnosis, a score above 4 and below 8 indicated a mild syndrome, that above 8 and below 12 indicated a moderate type, and that greater than or equal to 12 implied a severe type.…”

Efficacy and safety of traditional Chinese medicine injections in the treatment of chronic obstructive pulmonary disease

“…[6][7][8] Existing evidence method of traditional Chinese medicine in the treatment of COPD has gained rich experience, and combining traditional Chinese and western medicine treatment can further improve the prognosis of patients. [9,10] Traditional Chinese medicine injections (TCMIs) treating COPD at present mainly include Tanreqing injection (TRQI), Danhong injection (DHI), Xuebiqing injection (XBQI), Shenmai injection (SMI), Huangqi injection (HQI), etc. [11] Studies have confirmed that XBQI can regulate the levels of SP-D and CCL18 in patients with COPD and alleviate the clinical symptoms of patients.…”